Mouse Endoglin/CD105 Antibody

Detection of Mouse Endoglin/CD105 by Western Blot. Western blot shows lysates of bEnd.3 mouse endothelioma cell line and MS-1 mouse pancreatic islet endothelial cell line. PVDF membrane was probed with 0.5 µg/mL of Goat Anti-Mouse Endoglin/CD105 Antigen Affinity-purified Polyclonal Antibody (Catalog # AF1320) followed by HRP-conjugated Anti-Goat IgG Secondary Antibody (Catalog # HAF017). A specific band was detected for Endoglin/CD105 at approximately 90-95 kDa (as indicated). This experiment was conducted under reducing conditions and using Immunoblot Buffer Group 1.

Endoglin/CD105 in MS-1 Mouse Cell Line. Endoglin/CD105 was detected in immersion fixed MS-1 mouse pancreatic islet endothelial cell line using Goat Anti-Mouse Endoglin/CD105 Antigen Affinity-purified Polyclonal Antibody (Catalog # AF1320) at 10 µg/mL for 3 hours at room temperature. Cells were stained using the NorthernLights™ 557-conjugated Anti-Goat IgG Secondary Antibody (yellow; Catalog # NL001) and counter-stained with DAPI (blue). View our protocol for Fluorescent ICC Staining of Cells on Coverslips.

Endoglin/CD105 in Rat Mesenchymal Stem Cells. Endoglin/CD105 was detected in immersion fixed rat mesenchymal stem cells using Goat Anti-Mouse Endoglin/CD105 Antigen Affinity-purified Polyclonal Antibody (Catalog # AF1320) at 10 µg/mL for 3 hours at room temperature. Cells were stained using the NorthernLights™ 557-conjugated Anti-Goat IgG Secondary Antibody (red; Catalog # NL001) and counterstained with DAPI (blue). Specific staining was localized to cytoplasm. View our protocol for Fluorescent ICC Staining of Cells on Coverslips.

Endoglin/CD105 in Mouse Embryo. Endoglin/CD105 was detected in immersion fixed frozen sections of mouse embryo (E13-15) using Goat Anti-Mouse Endoglin/CD105 Antigen Affinity-purified Polyclonal Antibody (Catalog # AF1320) at 15 µg/mL overnight at 4 °C. Tissue was stained using the Anti-Goat HRP-DAB Cell & Tissue Staining Kit (brown; Catalog # CTS008) and counterstained with hematoxylin (blue). Lower panel shows a lack of labeling if primary antibodies are omitted and tissue is stained only with secondary antibody followed by incubation with detection reagents. View our protocol for Chromogenic IHC Staining of Frozen Tissue Sections.

Detection of Mouse Endoglin/CD105 by Simple Western^TM. Simple Western lane view shows lysates of bEnd.3 mouse endothelioma cell line, loaded at 0.2 mg/mL. A specific band was detected for Endoglin/CD105 at approximately 121 kDa (as indicated) using 5 µg/mL of Goat Anti-Mouse Endoglin/CD105 Antigen Affinity-purified Polyclonal Antibody (Catalog # AF1320) followed by 1:50 dilution of HRP-conjugated Anti-Goat IgG Secondary Antibody (Catalog # HAF109). This experiment was conducted under reducing conditions and using the 12-230 kDa separation system.

Detection of Porcine Endoglin/CD105 by Immunohistochemistry Chronic intermittent hypoxia modifies the BM vascular structure. a’–e’ Representative images of femur bone marrow stained with vWF, CD105, VE-cadherin, SMA, and CD11b counterstained with hematoxylin. a”, c”, d” BM from CIH exposed rats (n = 6) has more VE-cadherin+ vessels and SMA coverage but less vWF+ sinusoids (400×, Leica DM2500). e’, e” Representative images of CD11b immunohistochemistry in femur BM show an increase in BM monocyte count in CIH exposed animals. (400×, Leica DM2500) a’, a”’, b’, b” No changes in the total number of vessels or in megakaryocyte count were observed, as accounted by CD105 and vWF staining, respectively. Results are represented as the mean ± SD of bone marrow sections from six male Wistar rats (*p < 0.05; **p < 0.01). f Representative images of femur bone marrow fluorescently immunostained for VE-cadherin show an increase in total VE-cadherin vessels and in VE-cadherin vessel coverage. Scale bar, 50 μm (insets magnified 2.5×). Images were acquired with a Zeiss LSM 510 META microscope. Image collected and cropped by CiteAb from the following open publication (https://pubmed.ncbi.nlm.nih.gov/26856724), licensed under a CC-BY license. Not internally tested by R&D Systems.

Detection of Mouse Endoglin/CD105 by Immunohistochemistry Increased tumor necrosis and reduced tumor vascularization after GET of therapeutic plasmids in vivo.Histologically stained and analyzed sections after treatments of TS/A tumors: intratumoral injection of endotoxin-free water alone (control group; CTRL) or in combination with the application of electric pulses (EP group), injection of plasmid pET-antiCD105 (TS group), pU6-antiCD105 (CON group) or pU6-SCR (SCR group) alone or combined with the application of electric pulses (GET of TS plasmid; GET of CON plasmid; GET of SCR plasmid). Triple GET of CON or TS plasmid increased necrosis (HE) and reduced the number of blood vessels (CD105) in TS/A tumors. The percentage of necrosis (upper graph) was statistically significantly increased (*p<0.05) in both of the therapeutic groups (GET of CON and TS plasmid) vs. all the pertinent control groups, with no difference between therapies, also seen in histological sections. The reduced number of blood vessels (CD105) was observed in histological sections of both therapeutic groups that were (lower graph) non-statistically significant to each other after analysis, although the reduction was statistically significant (*p<0.05) vs. all the pertinent control groups. The results represent one experiment, n = 3–4 mice for each experimental group and at least 5 analyzed fields of view for each mouse. The data represent AM ± SEM. N.S. represents statistically non-significant difference between the therapeutic groups. Scale bar = 100 μm. Image collected and cropped by CiteAb from the following open publication (https://dx.plos.org/10.1371/journal.pone.0124913), licensed under a CC-BY license. Not internally tested by R&D Systems.

Detection of Mouse Endoglin/CD105 by Immunohistochemistry Increased tumor necrosis and reduced tumor vascularization after GET of therapeutic plasmids in vivo.Histologically stained and analyzed sections after treatments of TS/A tumors: intratumoral injection of endotoxin-free water alone (control group; CTRL) or in combination with the application of electric pulses (EP group), injection of plasmid pET-antiCD105 (TS group), pU6-antiCD105 (CON group) or pU6-SCR (SCR group) alone or combined with the application of electric pulses (GET of TS plasmid; GET of CON plasmid; GET of SCR plasmid). Triple GET of CON or TS plasmid increased necrosis (HE) and reduced the number of blood vessels (CD105) in TS/A tumors. The percentage of necrosis (upper graph) was statistically significantly increased (*p<0.05) in both of the therapeutic groups (GET of CON and TS plasmid) vs. all the pertinent control groups, with no difference between therapies, also seen in histological sections. The reduced number of blood vessels (CD105) was observed in histological sections of both therapeutic groups that were (lower graph) non-statistically significant to each other after analysis, although the reduction was statistically significant (*p<0.05) vs. all the pertinent control groups. The results represent one experiment, n = 3–4 mice for each experimental group and at least 5 analyzed fields of view for each mouse. The data represent AM ± SEM. N.S. represents statistically non-significant difference between the therapeutic groups. Scale bar = 100 μm. Image collected and cropped by CiteAb from the following open publication (https://dx.plos.org/10.1371/journal.pone.0124913), licensed under a CC-BY license. Not internally tested by R&D Systems.